Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: Voltage regulator circuits and methods therefor provided. In some embodiments, a voltage regulator circuit comprises: a first switch coupled to a power input; a second switch coupled to the first switch; a switching node between the first switch and the second switch; an inductor coupled between the switching node and an output node; a capacitor coupled between the output node and ground; a driver configured to operate the first and second switches according to a pulse-width-modulated (PWM) signal; a PWM circuit configured to generate the PWM signal based on at least an error signal; and a phase detector configured to generate the error signal based on a phase difference between the PWM signal and a clock reference signal.

Abstract: Voltage regulator circuits and methods therefor provided. In some embodiments, a voltage regulator circuit comprises: a first switch coupled to a power input; a second switch coupled to the first switch; a switching node between the first switch and the second switch; an inductor coupled between the switching node and an output node; a capacitor coupled between the output node and ground; a driver configured to operate the first and second switches according to a pulse-width-modulated (PWM) signal; a PWM circuit configured to generate the PWM signal based on at least an error signal; and a phase detector configured to generate the error signal based on a phase difference between the PWM signal and a clock reference signal.

Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.

Abstract: Disclosed herein is an intrusion resistant thermal laminating film having a first multilayer structure of a polyester polymer layer and an ethylene methyl acrylate copolymer layer adhered thereto. The first multilayer structure is exposed to UV radiation for an effective period. A first adhesive layer is on the first multilayer structure and is an ethylene vinyl acetate copolymer or an ethylene ethyl acrylate copolymer. The film also has a printed layer of a polyolefin or a polyvinyl chloride attached to the adhesive layer. The film has high clarity and is free of a primer. The printed layer cannot be separated from the first multilayer structure without destroying the film. The film exhibits no signs of orange peel.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: The invention relates to a restraint device, in particular for a motor vehicle, for reducing an abrupt sideward movement of an occupant in the case of an impact with an airbag which is inflatable by means of a gas generator when an accident situation occurs. It is provided that the airbag has at least one side chamber and one shoulder chamber which are connected together, wherein in the inflated state of the airbag the side chamber and the shoulder chamber form different main extension planes which run at an angle to one another. An anchoring strap is fastened at one end to the shoulder chamber and at the other end to the vehicle seat. The shoulder chamber comprises two regions which transition into one another and which together form a reverse U-shape, the base thereof in the inflated state of the shoulder chamber forming the upper end thereof.

Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.

Abstract: Adaptive on-time switching voltage regulator circuits and methods therefor provided. In some embodiments, a voltage regulator comprises: a switching circuit configured to generate a switching signal at a switching node according to a pulse-width modulated (PWM) signal; a phase-lock loop (PLL) configured to lock the PWM signal to a clock reference signal, the PLL comprising: a PWM signal generator configured to generate the PWM signal according to an error signal, and a phase detector configured to generate the error signal based on the PWM signal and the clock reference signal.

Abstract: Voltage regulator circuits and methods therefor provided. In some embodiments, a voltage regulator circuit comprises: a first switch coupled to a power input; a second switch coupled to the first switch; a switching node between the first switch and the second switch; an inductor coupled between the switching node and an output node; a capacitor coupled between the output node and ground; a driver configured to operate the first and second switches according to a pulse-width-modulated (PWM) signal; a PWM circuit configured to generate the PWM signal based on at least an error signal; and a phase detector configured to generate the error signal based on a phase difference between the PWM signal and a clock reference signal.

Abstract: Adaptive on-time switching voltage regulator circuits and methods therefor provided. In some embodiments, a voltage regulator comprises: a switching circuit configured to generate a switching signal at a switching node according to a pulse-width modulated (PWM) signal; a phase-lock loop (PLL) configured to lock the PWM signal to a clock reference signal, the PLL comprising: a PWM signal generator configured to generate the PWM signal according to an error signal, and a phase detector configured to generate the error signal based on the PWM signal and the clock reference signal.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: Voltage regulator circuits and methods therefor provided. In some embodiments, a voltage regulator circuit comprises: a first switch coupled to a power input; a second switch coupled to the first switch; a switching node between the first switch and the second switch; an inductor coupled between the switching node and an output node; a capacitor coupled between the output node and ground; a driver configured to operate the first and second switches according to a pulse-width-modulated (PWM) signal; a PWM circuit configured to generate the PWM signal based on at least an error signal; and a phase detector configured to generate the error signal based on a phase difference between the PWM signal and a clock reference signal.

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Abstract: A permeable pavement system including a permeable pavement composition and a related method are provided. The permeable pavement system includes a first layer of a permeable pavement composition including a quantity of a first permeable pavement material and a quantity of cured carbon fiber composite material (CCFCM) incorporated therewith, the first layer defining a first surface; and a second layer of a second permeable pavement material deposited over a substantial entirety of and covering the first surface of the first layer of the permeable pavement composition, wherein the first layer interfaces with the second layer to at least strengthen the permeable pavement system.

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Abstract: The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.